Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

Phase 2 Double-blinded, Placebo-controlled, Clinical Trial for Safety and Efficacy of Methylprednisolone Infiltration in Anserine Bursitis Treatment

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01205477

Enrollment

Registered

2010-09-20

Start date

2009-09-30

Completion date

2010-07-31

Last updated

2010-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bursitis

Keywords

Anserine bursitis

Brief summary

To investigate the safety and efficacy of methylprednisolone infiltration in anserine bursitis treatment

Interventions

DRUGEXPERIMENTAL

Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

DRUGPLACEBO

Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of anserine bursitis

Exclusion criteria

* Intraarticular pathology that reflects pain in the medial part of the knee

Design outcomes

Primary

Measure	Time frame	Description
WOMAC score	4 weeks	The WOMAC (Westren Ontario and McMaster Universities) index is used to assess patients with osteoarthritis of the hip or knee using 24 parameters. It can be used to monitor the course of the disease or to determine the effectiveness of anti-rheumatic medications. Pain, Stiffness and Physical functionVisual analogue scale (VAS) may be used ranging from 0 to 10.

Secondary

Measure	Time frame	Description
VAS satisfaction	4 weeks	Visual Analoge Scale for satisfaction
Improvement	4 weeks	Percentage of improvement
SAFETY	4 weeks	Pain at infiltration site, ecchymosis, bleeding, paresthesias, skin infection, anaphilaxy, vasovagal reaction

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026